Xilio reports Q2 2026 results; FDA clears IND for XTX501 bispecific PD-1/masked IL-2

Xilio Therapeutics, Inc.

FDA cleared IND for XTX501 (bispecific PD-1/masked IL-2); Phase 1/2 dosing expected 2H 2026 in NSCLC and solid tumors; initial data 2H 2027.
Cash and equivalents $136.0M at 6/30/26 vs $137.5M at 12/31/25; runway into Q1 2028 (excl. warrant proceeds and milestones).
Q2 2026 collaboration revenue $18.7M vs $8.1M YoY; net loss $6.4M vs $15.8M YoY.
IND-enabling studies for masked TCEs targeting CLDN18.2 and PSMA+STEAP1; INDs planned 2H 2027.
Appointed Ben Harshbarger as Chief Legal Officer in June 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.